• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic posts Q2 EPS beat, misses on revenues as U.S. sales dip

Medtronic posts Q2 EPS beat, misses on revenues as U.S. sales dip

November 23, 2021 By Sean Whooley

MedtronicMedtronic (NYSE:MDT) shares are down this morning on second-quarter results that missed the consensus revenue forecast.

MDT shares were down 0.4% at $116.40 per share before the market opened today. Shares have since dipped down 2.5% at $113.93 per share after the market opened.

The Fridley, Minnesota-based medtech giant posted profits of $1.3 billion, or 97¢ per share, on sales of $7.8 billion for the three months ended Oct. 29, 2021, nearly tripling its bottom-line on sales growth of 2.6%.

Adjusted to exclude one-time items, earnings per share were $1.32, 3¢ ahead of Wall Street, where analysts were looking for sales of $8 billion.

Each of Medtronic’s major business arms saw year-over-year global revenue growth, with cardiovascular (up 3.7%) and neuroscience (3.5%) increasing the most. Medtronic’s diabetes business saw increased revenues of 1.9% and its medical surgical segment increased by 0.6%.

The largest dip came within the medsurg business, with the company’s respiratory, gastrointestinal and renal dealings dipping in revenues by 10.2%. Cranial and spinal technologies (within the neuroscience business) fell 0.4%.

Medtronic took a big hit in its U.S. business, with all segments experiencing revenue dips. Diabetes was hit hardest, dropping 8.1%, followed by medsurg (2.6% decrease), cardiovascular (0.3%) and neuroscience (0.2%).

“Our second-quarter results reflect focused execution of our strategy and the strong underlying health of the business, despite the market impact of the pandemic resurgence and healthcare system staffing challenges on medical procedure volumes, particularly in the U.S., which affected our quarterly revenue growth,” Medtronic Chairman & CEO Geoff Martha said in a news release. “During the quarter, we continued to advance our pipeline, launched new products, and grew share in the majority of our businesses. Looking ahead, as our markets recover, Medtronic is one of the best-positioned companies in healthcare.

“We have an expansive pipeline of leading technology, a robust balance sheet, and an expanding roster of proven top talent. Coupled with our revitalized operating model and new competitive mindset, we’re poised to accelerate and sustain growth.”

Medtronic reaffirmed its expectation to log adjusted EPS of between $5.65 and $5.75 for the full year. The company, citing the greater-than-expected market impact of COVID-19 and healthcare system staffing challenges, updated its prior sales guidance for growth between 7% and 8%, a slight decrease from previous projections of 9% growth.

Truist analysts David Rescott and Samuel Brodovsky wrote in a report that the revenue miss and lowered guidance wasn’t too much of a surprise as a result of the ongoing issues created by COVID-19. Additionally, analysts see the reiterated EPS guide as a positive indicator of the company’s model under the current environment.

Filed Under: Business/Financial News, Cardiovascular, Diabetes, Featured, MassDevice Earnings Roundup, Neurological, News Well, Surgical, Wall Street Beat Tagged With: Medtronic

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy